Ferozsons Laboratories Limited (PSX:FEROZ)

Market Cap	17.56B +29.5%
Revenue (ttm)	22.22B +32.1%
Net Income	933.38M +35.5%
EPS	21.47 +35.5%
Shares Out	43.47M
PE Ratio	18.82
Forward PE	n/a
Dividend	4.00 (0.99%)
Ex-Dividend Date	Oct 16, 2025

Volume	23,746
Average Volume	42,418
Open	411.00
Previous Close	405.82
Day's Range	401.00 - 412.99
52-Week Range	242.33 - 475.00
Beta	0.51
RSI	62.51
Earnings Date	Apr 29, 2026

About Ferozsons Laboratories

Ferozsons Laboratories Limited, together with its subsidiaries, engages in the importing, manufacturing, and sale of pharmaceutical products and medical devices in Pakistan, Afghanistan, Sri Lanka, the Philippines, Kenya, Myanmar, Kyrgyzstan, Mongolia, Cambodia, and internationally. The company offers products in various therapeutic areas of anti-fungal, anti-viral, antibiotics, cardiometabolic, cough, dermatology, diabetes, gastrointestinal and liver, oncology, orthopedic, and urology and nephrology areas. It also provides medical devices in t...

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 1954
• Employees: 1,556
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: FEROZ

Financial Performance

In fiscal year 2025, Ferozsons Laboratories's revenue was 18.86 billion, an increase of 18.94% compared to the previous year's 15.85 billion. Earnings were 776.54 million, an increase of 13.67%.